Dr Triona Ni Chonghaile aims to understand the role of the bromodomain proteins in the progression of invasive lobular breast cancer, a subtype of breast cancer that occurs in 15% of cases. The researchers aim to investigate if a small molecule drug, JQ1, can target the bromodomain proteins and stop lobular breast cancer’s growth.   


Dr Khaled will be researching how BCL11A and other proteins interact in triple negative breast cancer cells and how these interactions affect the rest of the cell. He hopes that this information could lead to new targeted treatments for this form of the disease.



Dr Fiona Kennedy will investigate the feasibility of an online resource to offer support to secondary breast cancer patients and help them to manage their symptoms with the ultimate aim of improving their overall quality of life.

Dr Anna Git will be studying the role of molecules called mid-sized non-coding RNAs, which she believes could have a more important role in breast cancer than previously thought. Her work will lead to a better understanding of breast cancer, and hopefully improved treatments.

Using the immune system to target tumours has been hailed as one of the next great breakthroughs in treating cancers, with the potential to use the patient’s own immune cells to specifically recognise and attack cancer cells. However, there is still much to learn if we are to use these immunotherapies to safely and effectively treat breast cancer whilst avoiding damage to healthy tissues.

The drugs crizotinib and lorlatinib have the potential to be new treatments for various forms of breast cancer. Professor Lord and his team will be investigating how these drugs work and using that information to work out the best way to use them to benefit patients.